TRIMTECH raises £24m seed led by Cambridge Innovation Capital and SV Health Investors to advance neurodegenerative treatments

TRIMTECH Therapeutics develops targeted protein degradation medicines that selectively remove harmful protein aggregates, focusing on neurodegenerative and inflammatory diseases with limited existing treatment options.